^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zilovertamab (UC-961)

    i
    Company:
    Oncternal Therap, Shanghai Pharma
    Drug class:
    ROR1 inhibitor
    Related drugs:
    Apply
    A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (NCT03088878)
    Phase 1/2
    Oncternal Therapeutics, Inc
    Completed
    Last update posted :
    02/12/2025
    Initiation :
    01/03/2018
    Primary completion :
    09/25/2024
    Completion :
    09/25/2024
    BCL2
    |
    Imbruvica (ibrutinib) • zilovertamab (UC-961)
    Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer (NCT02776917)
    Phase 1
    Barbara Parker, MD
    Completed
    Last update posted :
    04/10/2024
    Initiation :
    08/15/2018
    Primary completion :
    07/13/2021
    Completion :
    02/26/2024
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative
    |
    paclitaxel • zilovertamab (UC-961)
    Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 (NCT02860676)
    Phase 1
    University of California, San Diego
    Completed
    Last update posted :
    03/20/2019
    Initiation :
    11/03/2016
    Primary completion :
    02/27/2018
    Completion :
    05/22/2018
    CD19 • CD5
    |
    zilovertamab (UC-961)
    A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (CIRLL study) (NCT03420183)
    Phase 1b
    Oncternal Therapeutics, Inc
    Recruiting
    Last update posted :
    02/20/2019
    Initiation :
    02/13/2018
    Primary completion :
    04/01/2019
    Completion :
    12/01/2022
    ROR1
    |
    Imbruvica (ibrutinib) • zilovertamab (UC-961)